Decitabine in Treating Patients With Advanced Solid Tumors

Inclusion Criteria:

• Diagnosis of advanced metastatic solid tumor for which all standard therapy has failed, including, but not limited to the following:

  • Stage III or IV melanoma

    • Mucosal melanoma allowed
    • No resectable stage III melanoma
  • Bladder cancer
  • Breast cancer
• No active symptomatic CNS disease
• No radiographically evident cerebral edema

• Hormone receptor status:

  • Not specified
• Male or female
• Performance status - ECOG 0-1
• Hemoglobin at least 9.0 g/dL
• Platelet count at least 100,000/mm^3
• WBC at least 3,500/mm^3
• Absolute granulocyte count at least 1,500/mm^3
• No coagulation disorders
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• SGOT and SGPT less than 2.5 times ULN
• Hepatitis B surface antigen negative
• Hepatitis C antibody negative
• Creatinine no greater than 1.5 times ULN
• No major cardiovascular system illness
• No major respiratory system illness
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No major systemic infection
• At least 1 month since prior radiotherapy
• At least 1 month since any prior anticancer therapy or adjuvant therapy
• No other experimental treatment within 30 days prior to, during, and for 30 days after study therapy